OABK hydrochloride

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway:	HY-100825 1984862-48-7 C ₁₄ H ₂₀ ClN ₅ O ₄ 357.79 Others Others	
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

SOLVENT & SOLUBILITY

In Vitro DMSO : 25 mg/mL (Preparing Stock Solutions		Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	2.7949 mL	13.9747 mL	27.9494 mL		
	5 mM	0.5590 mL	2.7949 mL	5.5899 mL			
		10 mM	0.2795 mL	1.3975 mL	2.7949 mL		
	Please refer to the so	lubility information to select the ap	propriate solvent.				
ı Vivo		1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.99 mM); Clear solution					
		2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.99 mM); Clear solution					
		 Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.99 mM); Clear solution 					

BIOLOGICAL ACTIVITY			
BIOLOGICAL ACTIVITY			
Description	OABK hydrochloride is a small-molecule switch that can be used to control protein activity. OABK (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.		
In Vitro	A small-molecule switch for the activation of protein function through the site-specific incorporation of an ortho- azidobenzyloxycarbonyl lysine (OABK). The amino acid OABK is synthesized readily in three steps from 2-azidobenzyl alcohol via a succinimidyl carbonate. Deprotection results in the formation of lysine and, when OABK is incorporated into a protein, the formation of active wild-type protein. Genetically encoded OABK in conjunction with small-molecule activation		



allows for the conditional regulation of intracellular protein maturation. Incorporation of OABK (0.5 mM) at position K85 of	
EGFP inhibits fluorophore formation until the native lysine is generated through small-molecule activation (the model is	
based on Protein Data Bank (PDB). Introducing OABK at position K206 inhibits FLuc enzymatic activity by restricting the	
access of adenosine triphosphate (ATP) to the active site, until the enzyme is deprotected and activated through phosphine	
treatment. The incorporation of OABK into FLuc blocks the luciferase activity in the absence of small-molecule activation, as	
determined by a Bright-Glo luciferase assay ^[1] .	

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL	
Cell Assay ^[1]	HEK293T cells are plated at 100,000 cells per well (400 μL) into a poly-D-lysine-coated eight-well chamber slide. At 75% confluency, cells are co-transfected with pEGFP-K85TAG-mCherry or pEGFP-K29TAG-SatB1-mCherry and pOABKRS-4PyIT (200 ng of each plasmid) using linear PEI (3 μL, 0.323 mg/mL). After 20 hours of incubation at 37°C and 5% CO ₂ in DMEM with 10% FBS in the presence of OABK (0.25 mM), the cells are washed three times with phenol-red-free DMEM (200 μL), followed by three hours of incubation to remove any non-incorporated OABK. Before small-molecule activation, the cells are focused using the Texas Red channel, and imaged with a Nikon A1 confocal microscope (×40 oil objective, ×2 zoom, fluorescein isothiocyanate (ex=488 nm) and Texas Red (ex=560 nm) channels) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Luo J, et al. Small-molecule control of protein function through Staudinger reduction. Nat Chem. 2016 Nov;8(11):1027-1034.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA